您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Seratrodast
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Seratrodast
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Seratrodast图片
CAS NO:112665-43-7
包装与价格:
包装价格(元)
25mg电议
50mg电议

产品介绍

化学性质

StorageStore at -20°C
M.Wt354.4
Cas No.112665-43-7
FormulaC22H26O4
SynonymsAA2414,A-73001,ABT-001
Solubility≥10.9 mg/mL in DMSO
Chemical Nameζ-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-benzeneheptanoic acid
Canonical SMILESOC(CCCCCC(C1=CC=CC=C1)C(C(C(C)=C2C)=O)=C(C)C2=O)=O
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

IC50: 7.4 nM for guinea pig platelets

Seratrodast is a thromboxane A2 (TXA2) receptor antagonist.

Thromboxane A2, a type of thromboxane, is produced by activated platelets and has prothrombotic properties, such as stimulating activation of new platelets and increasing platelet aggregation.

In vitro: Seratrodast was found to inhibit the aggregation of guinea pig platelets induced by a prostaglandin endoperoxide analogue, U-44069 and the specific binding of another analogue, [3H]U-46619 to washed guinea pig platelets. Seratrodast could competitively inhibit the contraction of rabbit aorta and pig coronary arteries induced by U-44069. Seratrodast also inhibited the contraction of rabbit aorta induced by PGF2 alpha and the contraction of pig coronary arteries. However, seratrodast had no effect on the antiaggregatory effect of guinea pig platelets [1].

In vivo: In experiments with guinea pigs, oral seratrodast at 0.1-1 mg/kg could dose-dependently inhibit the platelet aggregation induced by U-44069; the inhibition at 1 mg/kg was 100% at 1 hr and was 89% even at 24 hr after seratrodast administration [1].

Clinical trial: So far, no clinical study has been conducted.

Reference:
[1] Imura, Y. ,Terashita, Z.,Shibouta, Y., et al. Antagonistic action of AA-2414 on thromboxane A2/prostaglandin endoperoxide receptor in platelets and blood vessels. Japanese Journal of Pharmacology 52(1), 35-53 (1990).